Medincell (LTS:0ACH) Other Stockholders Equity: €3.06 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0ACH Medincell SA LTS:0ACH
78 GF Score
Price €26.88
GF Value €21.95
Valuation Modestly Overvalued
! 5 Warning Signs
View Full Analysis

What is Medincell Other Stockholders Equity?

Medincell LTS:0ACH -0.81% 78 Other Stockholders Equity is €3.06 Mil as of Mar. 2026. GuruFocus rates LTS:0ACH with a GF Score™ of 78/100 and a GF Value™ of €21.95 (Modestly Overvalued). The stock has 5 warning signs investors should review.

Medincell's Other Stockholders Equity for the quarter that ended in Mar. 2026 was €3.06 Mil.

Medincell's quarterly Other Stockholders Equity increased from Mar. 2025 (€-68.99 Mil) to Sep. 2025 (€-14.98 Mil) and increased from Sep. 2025 (€-14.98 Mil) to Mar. 2026 (€3.06 Mil).

Medincell's annual Other Stockholders Equity declined from Mar. 2024 (€-47.09 Mil) to Mar. 2025 (€-68.99 Mil) but then increased from Mar. 2025 (€-68.99 Mil) to Mar. 2026 (€3.06 Mil).

Medincell Other Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Medincell's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medincell Other Stockholders Equity Chart

Medincell Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Other Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.27 -17.95 -47.09 -68.99 3.06

Medincell Semi-Annual Data
Mar16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -47.09 -70.91 -68.99 -14.98 3.06
LTS:0ACH
78GF Score
Medincell SA LTS:0ACH
Other Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Medincell Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

What does a Other Stockholders Equity of €3.06 Mil mean?
Medincell (LTS:0ACH) has a Other Stockholders Equity of €3.06 Mil as of Mar. 2026. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Medincell and its competitors.
Is Medincell's Other Stockholders Equity too high?
Medincell's current Other Stockholders Equity is €3.06 Mil. Overall, Medincell has a GF Score™ of 78/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Medincell's Other Stockholders Equity compare to VRTX and REGN?
Medincell's Other Stockholders Equity of €3.06 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Biotechnology company?
A good Other Stockholders Equity depends on the Biotechnology industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Medincell and its competitors. Medincell's current Other Stockholders Equity is €3.06 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medincell stock overvalued right now?
Based on GuruFocus' analysis, Medincell (LTS:0ACH) is currently considered Modestly Overvalued. The stock's GF Value™ is €21.95, compared to a current price of €26.88 — trading 22.5% above its estimated fair value. The current Other Stockholders Equity is €3.06 Mil. Medincell's overall GF Score™ is 78/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For Medincell (LTS:0ACH), the current Other Stockholders Equity is €3.06 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Medincell (LTS:0ACH) Overvalued in 2026?

Based on GuruFocus' analysis, Medincell stock appears to be overvalued. The current stock price of €26.88 is trading 22.5% above its estimated GF Value™ of €21.95. GuruFocus considers Medincell to be Modestly Overvalued.

Key valuation signals for LTS:0ACH:

  • Other Stockholders Equity: €3.06 Mil
  • GF Value™: €21.95 vs. price of €26.88 (22.5% above fair value)
  • GF Score™: 78/100 with 5 warning signs

No single metric tells the full story. See the LTS:0ACH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Medincell Business Description

Address 3 rue des Freres Lumiere, Jacou, FRA, 34830
Medincell SA is a technology-based pharmaceutical firm, aims to optimise the efficiency of medical treatments and make them accessible geographically. The company's product portfolio uses BEPO-patented technology to develop controlled, long-acting injectable medical treatments for a number of therapeutic fields. The firm has a single operating segment: ongoing research and development on processes that use biodegradable polymers to enable the controlled and prolonged release of the active principles of drugs into the human body and animals by means of injection.
78GF Score

Get the complete analysis for LTS:0ACH

Other Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€26.88
Price
€21.95
GF Value